Partnership leverages Replicate's proprietary srRNA technology to create novel, scalable therapies for obesity, type 2 diabetes and other cardiometabolic diseases Replicate will receive research ...
Novo Nordisk has turned to Replicate Bioscience’s RNA drug platform in a lucrative research collaboration, marking the latest effort by the big pharma company to diversify its pipeline in the hope of ...
California biotech Replicate Biosciences will receive up to $550 million from Novo Nordisk in an alliance that aims to track down new drugs for obesity and diabetes. The partners will develop new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results